Abstract: The present invention relates to a cancer sub-type. Provided are methods for determining clinical prognosis of a subject with cancer, selecting whether to administer an anti-angiogenic therapeutic agent to a subject with cancer and predicting responsiveness of a subject with cancer to an anti-angiogenic therapeutic agent. The methods are based on assessing from the expression level of biomarkers disclosed herein whether the cancer belongs to the sub-type. Companion methods of treating cancer and agents for use in treating cancer are also provided.

Abstract: The present invention relates to a method of indentifying an agent that modulates the function of an apoptosos-associated polypeptide having a sequence as set out in Table 1, the method comprising: (a) providing a sample containing an apoptosis-associated polypeptide having a sequence as set out in Table 1, and a candidate agent and incubating under conditions to permit binding of the candidate agent to the polypeptide; (b) measuring the binding of the apoptosis-associated polypeptide having a sequence as set out in Table 1 to the candidate agent in the sample; and (c) comparing the binding of the apoptosis-associated polypeptide having a sequence as set out in Table 1 to the candidate agent in the sample with the binding of the polypeptide having a sequence as set out in Table 1; wherein an increase in the binding of the apoptosis-associated polypeptide having a sequence as set out in Table 1 to the candidate agent in the sample relative to the binding of the apoptosis-associated polypeptide having a sequenc